Cargando…
Rituximab is not a “magic drug” in post-transplant recurrence of nephrotic syndrome
Pediatric patients with end-stage renal failure due to severe drug-resistant nephrotic syndrome are at risk of rapid recurrence after renal transplantation. Treatment options include plasmapheresis, high-dose of cyclosporine A/methylprednisolone and more recently—rituximab (anti-B CD(20) monoclonal...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer Berlin Heidelberg
2016
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5005389/ https://www.ncbi.nlm.nih.gov/pubmed/27364906 http://dx.doi.org/10.1007/s00431-016-2747-1 |